YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Antagonizing vascular endothelial growth factor receptor 2 (VEGFR2) to block angiogenesis has been applied toward cancer therapy for its role in promoting cancer growth and metastasis. However, most these clinical anticancer drugs have unexpected side effects. Development of novel VEGFR2 inhibitors...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Xia, Yong, Song, Xuejiao, Li, Deliang, Ye, Tinghong, Xu, Youzhi, Lin, Hongjun, Meng, Nana, Li, Guobo, Deng, Senyi, Zhang, Shuang, Liu, Li, Zhu, Yongxia, Zeng, Jun, Lei, Qian, Pan, Youli, Wei, Yuquan, Zhao, Yinglan, Yu, Luoting
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2014
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4129416/
https://ncbi.nlm.nih.gov/pubmed/25112436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep06031
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk